Antitumor effect of mifepristone on human endometrial stromal cell line

Jovan Luković; Zoran Milosavljević; Tanja Zečević Luković; Marina Mitrović; Marija Andjelković; Ivanka Zelen; Marijana  Stanojević Pirković; Ivana Nikolić

doi:10.2298/VSP190226104L

Jovan Luković University of Kragujevac, Faculty of Medical Sciences, Department of Biochemistry, Kragujevac, Serbia
Zoran Milosavljević University of Kragujevac, Faculty of Medical Sciences, Department of Histology and Embryology, Kragujevac, Serbia
Tanja Zečević Luković University of Kragujevac, Faculty of Medical Sciences, Department of Physical Medicine and Rehabilitation, Kragujevac, Serbia
Marina Mitrović University of Kragujevac, Faculty of Medical Sciences, Department of Biochemistry, Kragujevac, Serbia
Marija Andjelković University of Kragujevac, Faculty of Medical Sciences, Department of Biochemistry, Kragujevac, Serbia
Ivanka Zelen University of Kragujevac, Serbia, Faculty of Medical Sciences, Department of Biochemistry
Marijana Stanojević Pirković University of Kragujevac, Faculty of Medical Sciences, Department of Biochemistry, Kragujevac, Serbia
Ivana Nikolić University of Kragujevac, Faculty of Medical Sciences, Department of Biochemistry, Kragujevac, Serbia

DOI: https://doi.org/10.2298/VSP190226104L

Keywords: endometrial hyperplasia;, mifepristone;, apoptosis;, cell death;, carcinoma.

Abstract

Background/Aim. The main cause for development of endometrial hyperplasia is unopposed effect of estrogen on endometrial cells. The aim of our study was to investigate and compare cytotoxic and apoptotic effects of mifepristone on human endometrial stromal cell line for the first time. Both percentage of cytotoxic and apoptotic cells were determined after 24 h treatment with different doses of mifepristone. Methods. The percentage of cytotoxic cell was evaluated by viability assay while the percentage of apoptotic cells was determined using flow cytometry. Determination of apoptotic effects was confirmed using immunofluorescence method determining expression and localization of active Bax and Bcl-2 proteins. Results. Our results indicated that mifepristone induced cytotoxic and apoptotic effect on human endometrial stromal cell line (ThESC) through changes in expression level of Bcl-2 and active Bax proteins. Conclusion. Cytotoxic and pro-apoptotic effects of mifepristone on human endometrial stromal cell line in vitro was investigated in this study for the first time. It is crucial to point out that mifepristone expressed both cytotoxic and pro-apoptotic effect on ThESC cell line. Our results may contribute to determination of localization and expression level of the crucial proteins involved in apoptosis in ThESC cell line after the treatment with the lowest cytotoxic doses of mifepristone.

Author Biography

Ivanka Zelen, University of Kragujevac, Serbia, Faculty of Medical Sciences, Department of Biochemistry

University of Kragujevac, Serbia, Faculty of Medical Sciences, Department of Biochemistry

Vanredni profesor

References

Sivridis E, Giatromanolaki A. Demystifying endometrial hyper-plasia. Diagn Histopathol 2013; 19(7): 223–30.

Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplas-ia: a review. Obstet Gynecol Surv 2004; 59(5): 368–78.

Sanderson PA, Critchley HO, Williams AR, Arends MJ, Saunders PT. New concepts for an old problem: the diagnosis of endo-metrial hyperplasia. Hum Reprod Update 2017; 23(2): 232‒54.

Moore E, Shafi M. Endometrial hyperplasia. Obstet Gynaecol Reprod Med 2013; 23(3): 88–93.

Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, et al. Management of endometrial precancers. Obstet Gynecol 2012; 120(5): 1160–75.

Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 1997; 48: 129‒56.

Narvekar N, Cameron S, Critchley HO, Lin S, Cheng L, Baird DT. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J Clin Endocrinol Metab 2004; 89(5): 2491–7.

Sun Y, Fang M, Davies H, Hu Z. Mifepristone: a potential clin-ical agent based on its anti-progesterone and anti-glucocorticoid properties. Gynecol Endocrinol 2014; 30(3): 169‒73.

Telleria CM, Goyeneche AA. Antiprogestins in Ovarian Cancer. In: Farghaly S, editor. OvarianCancer – Clinical and Therapeu-tic Perspectives. Chapter 11. Rijeka, Croatia: InTechopen; 2012.

Mahajan DK, London SN. Mifepristone (RU486): a review. Fertil Steril 1997; 68(6): 967‒76.

Murphy AA, Zhou MH, Malkapuram S, Santanam N, Parthasara-thy S, Sidell N. RU486-induced growth inhibition of human endometrial cells. Fertil Steril 2000; 74(5): 1014–9.

Li A, Felix JC, Minoo P, Amezcua CA, Jain JK. Effect of mife-pristone on proliferation and apoptosis of Ishikawa endome-trial adenocarcinoma cells. Fertil Steril 2005; 84(1): 202–11.

Goyeneche AA, Caron RW, Telleria CM. Mifepristone Inhibits Ovarian Cancer Cell Growth In vitro and In vivo. Clin Can-cer Res 2007; 13(11): 3370–9.

Warren CFA, Wong-Brown MW, Bowden NA. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis 2019; 10(3): 177.

Deligdisch L. Hormonal pathology of the endometrium. Mod Pathol 2000; 13(3): 285‒94.

Goncharenko VM, Beniuk VA, Kalenska OV, Demchenko OM, Spivak MY, Bubnov RV. Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age. EPMA J 2013; 4(1): 24.

Linkov F, Edwards R, Balk J, Yurkovetsky Z, Stadterman B, Lokshin A, et al. Endometrial hyperplasia, endometrial cancer and prevention: Gaps in existing research of modifiable risk factors. Eur J Cancer 2008; 44(12): 1632–44.

Tieszen CR, Goyeneche AA, Brandhagen BN, Ortbahn CT, Telleria CM. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer 2011; 11(1): 207.

Wempe SL, Gamarra-Luques CD, Telleria CM. Synergistic le-thality of mifepristone and LY294002 in ovarian cancer cells. Cancer Growth Metastasis 2013; 6: 1‒13.

Smith JA, Gaikwad A, Burke T, Brown J, Ramondetta LM. In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A en-dometrial cancer cell lines. Cancer Chemother Pharmacol 2008; 62(3): 483–9.

Ørbo A, Moe BT, Grønaas H, Paulssen RH. Early effects of high concentrations of progesterone and mifepristone A gene ex-pression study of endometrial cancer cells (Ishikawa). J Steroid Biochem Mol Biol 2009; 113(1–2): 139–49.

Zhang M, Zheng J, Nussinov R, Ma B. Release of Cytochrome C from Bax Pores at the Mitochondrial Membrane. Sci Rep 2017; 7(1): 2635.

Stehle D, Grimm M, Einsele-Scholz S, Ladwig F, Johänning J, Fischer G, et al. Contribution of BH3-domain and Transmem-brane-domain to the Activity and Interaction of the Pore-forming Bcl-2 Proteins Bok, Bak, and Bax. Sci Rep 2018; 8: 12434.

Alves S, Neiri L, Chaves SR, Vieira S, Trindade D, Manon S, et al. N-terminal acetylation modulates Bax targeting to mito-chondria. Int J Biochem Cell Biol 2018; 95: 35–42.